论文部分内容阅读
目的:分析肿瘤化疗相关性死亡的原因和危险因素,总结治疗经验,为临床化疗的选用提供依据。方法:回顾性调查15例经过化疗死亡的病例的临床资料,分析化疗方案、化疗后存活时间、死亡原因和预防方法。结果:15例患者的平均年龄为52.4岁,其中5例使用含多西紫杉醇化疗方案,化疗后存活时间1～29d,平均为16.8d。有5例患者出现Ⅳ度骨髓抑制,其中2例并发肺部感染,4例出现呼吸衰竭。结论:肿瘤化疗相关性死亡与患者的既往病史、年龄和化疗药物等有关。对有肝肺肾病史、年龄>60岁的患者,避免使用含多西紫杉醇的化疗方案,可能减少肿瘤化疗相关性死亡。
Objective: To analyze the causes and risk factors of cancer chemotherapy-related death, summarize the experience of treatment, and provide the basis for the selection of clinical chemotherapy. Methods: The clinical data of 15 patients who died after chemotherapy were retrospectively analyzed. The chemotherapy regimen, the survival time after chemotherapy, the cause of death and the preventive measures were analyzed. Results: The average age of 15 patients was 52.4 years, of which 5 cases were treated with docetaxel chemotherapy, survival time after chemotherapy 1 ~ 29d, with an average of 16.8d. Four patients had grade IV myelosuppression in 5 patients, two of which developed pulmonary infection and four developed respiratory failure. Conclusions: The related deaths of chemotherapy and chemotherapy are related to the patient’s past medical history, age and chemotherapeutic drugs. Avoiding the use of docetaxel-containing chemotherapy in patients with a history of hepatorenal disease, age> 60 years, may reduce chemotherapy-related deaths in the tumor.